Speaker Profile

M.D., Chief Medical Officer, Immuno-Oncology, BeiGene

Dr. Amy C. Peterson, M.D. has been Chief Medical Officer of Immuno-Oncology at BeiGene, Ltd. since August 2016. Dr. Peterson will lead the global clinical development of BGB-A317, a PD-1 inhibitor; BGB-290, a PARP inhibitor and the expanding pipeline of other immuno-oncology agents expected to enter clinical development. Dr. Peterson expands BeiGenes senior medical leadership in response to emerging global development opportunities, particularly in immuno-oncology. She has broad experience in oncology drug development and academic background in immuno-oncology research. Prior to joining BeiGene, Dr. Peterson was Vice President of Clinical Development at Medivation, where she was primarily responsible for the development of enzalutamide and talazoparib in breast cancer and of pidilizumab in diffuse large b-cell lymphoma. Previously, she served as Associate Group Medical Director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. Dr. Peterson received her M.D. from Thomas Jefferson University in Philadelphia, PA and she completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. She holds a Bachelor of Arts degree from Wesleyan University in Middletown, CT.

Presentation Title and Company Description

Immunotherapy Showcase: Tislelizumab (BGB-A317) in Combination with Zanubrutinib (BGB-3111) or Pamiparib (BGB-290)
BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival.

Our lead product candidates are BGB-3111 and BGB-A317. BGB-3111 is a potent and highly selective small molecule BTK inhibitor that is currently being evaluated in dose expansion clinical trials as a monotherapy and in combination with other therapies to treat various lymphomas. BGB-A317 is a humanized monoclonal antibody against the immune checkpoint receptor PD-1. It is believed to be differentiated from the currently approved PD-1 antibodies with the ability to bind Fc gamma receptor I specifically engineered out, and has the potential to restore a T-cell’s cancer killing ability by inhibiting PD-1 and removing the blockade of immune activation against cancer.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.